Wegovy may be worth discussing if: You want the most extensive cardiovascular safety evidence alongside weight loss You are between 12 and 17 years old and need an approved GLP-1 option You have a history of heart disease, heart attack, or stroke and cardiovascular risk reduction is part of your treatment goal You prefer a medication with the longest and broadest clinical track record in its current class You want access to the new HD 7.2mg dose if your weight loss plateaus at 2.4mg Zepbound may be worth discussing if: Maximum average weight loss from clinical trials is your primary priority You have moderate-to-severe obstructive sleep apnea alongside obesity and want a medication approved for both You tried semaglutide and did not get the results you were hoping for You want a once-weekly injection without a type 2 diabetes diagnosis You are comfortable with a slightly newer medication and a still-growing long-term data set Mounjaro may be relevant if: You have a type 2 diabetes diagnosis and want a medication that manages both blood sugar and weight Your clinician recommends tirzepatide specifically and Mounjaro is the better-covered option under your insurance plan You want tirzepatide but your insurance covers Mounjaro and not Zepbound for your specific situation Note: if you do not have type 2 diabetes, Zepbound is the FDA-approved weight loss version of tirzepatide and will generally be the correct choice between the two
He/she can serve as a host in which the virus mutates making it more virulent, which when youre exposed a second time, may make you sick
GLP-1 medications are changing how we think about treating obesity and metabolic disease, says Robert Kushner, MD, professor of medicine at Northwestern University and an obesity medicine specialist
Moreover, the cell proliferation ability of HCC cell lines (MHCC97H and HepG2) and PCa cell lines (LNCaP and C4-2) increased with an increase in Gln concentration, as determined by cell CCK- 8 and colony formation assays (Fig
A systematic review of waist-to-height ratio as a screening tool for the prediction of cardiovascular disease and diabetes: 05 could be a suitable global boundary value
No ingredient list
